Transcatheter aortic valve replacement is a minimally invasive procedure used to treat aortic stenosis, a serious valve condition in which blood flow to the heart is restricted by a narrowing of the aortic valve opening. The procedure replaces the aortic valve without open-heart surgery.
The American College of Cardiology issued the certification after a nine-month evaluation that analyzed key areas at Mount Sinai Heart, including clinical outcomes, patient experience and infection control guidelines.
Earlier this year, U.S. News & World Report issued a “high performing” rating for Mount Sinai’s TAVR, among other procedures.
More articles on cardiology:
Duke surgeons perform 1,500th heart transplant
Devicemaker payments may influence cardiologists’ implant choice, study finds
5 pediatric heart practices cardiologists should question
Leave a Reply